Phio Pharmaceuticals Corp. Common Stock (PHIO)
Phio Pharmaceuticals Corp. (PHIO) is a biotechnology company that focuses on developing immuno-oncology therapies using its proprietary RNA interference (RNAi) platform. The company aims to enhance the body's immune response to cancer by targeting and modulating specific genes involved in tumor immune evasion.
Company News
The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.
Phio Pharmaceuticals reported a Q2 2025 net loss of $2.2 million, with its lead candidate PH-762 showing promising early clinical results in cancer therapy. The company's INTASYL platform demonstrated positive safety and efficacy signals in gene-silencing cancer treatments.
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers XBP Europe Holdings, Inc. (NASDAQ: XBP) shares rose 150% to $14.20 in pre-...
Penny stocks to buy? Here are some of the most active under $5 to watch. The post Penny Stocks To Buy Now? 5 Under $5 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.